[1] Uetrecht J. Idiosyncratic drug reactions: current understanding[J]. Annu. Rev. Pharmacol. Toxicol,2007,47:513-539. [2] Vogel F,Jager P. The genetic load of a human population due to cytostatic agents[J]. Humangenetic, 1969,7:287-304. [3] Hetherington S, Hughes A R, Mosteller M,et al.Genetic variations in HLA-B region and hypersensitivity reactions to abacavir[J]. Lancet ,2002,359:1121-1122. [4] Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir[J].Lancet,2002,359:727-732. [5] Hughes D A, Vilar F J, Ward C C, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hyperse- nsitivity[J]. Pharmacogenetics,2004,14:335-342. [6] Hung S I,Chung W H,,Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J].Pharmacog-enet Genomics, 2006,16:297-306. [7] Chung W H, Hung S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome[J]. Nature 2004 ,428(6982):486. [8] Alfirevic A, Jorgensen A L, Williamson P R, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity[J]. Pharmacogenomics ,2006 ,7: 813-818. [9] Lonjou C, Thomas L, Borot N, et al.A marker for Stevens Johnson syndrome:ethnicity matters[J].Pharmacogenomics,2006,6:265-268. [10] Saag M, Balu R, Phillips E,et al. High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity(ABC HSR)[R]. Presented at 4th International AIDS Society Meeting, Sydney, Australia 2007. [11] Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity[J]. Circulation, 2005,112: 3754-3762. [12] Mushiroda T, Saito S, Tanaka Y,et al.A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms[J]. J. Hum. Genet,2005,50:442-447. [13] Makita N, Horie M, Nakamura T,et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation[J].Circulation,2002, 106:1269-1274. (因版面有限,部分参考文献省略,如有需要,请联系编辑部) |